Primmune Therapeutics

Primmune Therapeutics is developing an orally administered TLR7 agonist to stimulate innate immunity in cancer immunotherapy. Their goal is to improve the response rate of patients to current and future immunotherapy medicines.

Industries

Stage

Series A

Employees

1-10

Links

Org chart

Charles McDermott
Chairman, President & CEO
Collapse
Richard Daniels
Chief Operating Officer
Paulo Rangel
Chief Business Officer & Co-Founder
James Appleman
SVP, R&D & CSO Co-Founder, Director
Curtis Scribner
Chief Medical Officer
Scott Zook
Senior Vice President Global Manufacturing
Stephen E. Webber
VP, Medicinal Chemistry, & Co-Founder